MedTrace Logo

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NCT06315010 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-25

No results posted yet for this study

Summary

REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.

Conditions

Interventions

DRUG

Repotrectinib

Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules. Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid.

Sponsors & Collaborators

  • Medical University of Vienna

    collaborator OTHER

  • MedSIR

    lead OTHER

Principal Investigators

  • Matthias Preusser, md · Medical University of Vienna, Vienna General Hospital (Austria)

  • Barbara Kiesewetter, MD · Medical University of Vienna, Vienna General Hospital (Austria)

  • Thorsten Füreder, MD · Medical University of Vienna, Vienna General Hospital (Austria)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2027-03-31
Completion
2028-04-30

Countries

  • Austria
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06315010 on ClinicalTrials.gov